Compare Ascendis Pharma A/S (ASND) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Waste Management, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Waste Management, Inc. trades at $236.4 (market cap $93.70B). The key difference: Waste Management, Inc. is far larger — about 5.3× Ascendis Pharma A/S's market cap, and Waste Management, Inc. pays a 1.52% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WM | |
|---|---|---|
Market Cap | $17.74B | $93.70B |
Sector | Health | Industrials |
52-Week High | $277.18 | $246.51 |
52-Week Low | $163.32 | $196.77 |
Enterprise Value | $18.11B | $116.43B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
WM trades at $233.33, up 0.72% today, showing steady performance near its 52-week high. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters show mixed earnings results. Analyst consensus remains positive with a $263.57 price target. The company continues its dividend payments, with the next $0.95 dividend scheduled for June 2026.
Outlook: WM's defensive business model and pricing power provide stability, but elevated valuation ratios (P/E 33.77) pose risks if growth slows. Upside potential exists if the company meets Q2 2026 earnings expectations. Key risks include debt levels and economic sensitivity. Wall Street's strong buy sentiment (57% buy ratings) supports a cautiously optimistic view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
